CoChat

The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.

Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells

Open access

Abstract

The rise of drug resistance in cancer cells presents a formidable challenge in modern oncology, necessitating the exploration of innovative therapeutic strategies. This review investigates the latest advancements in overcoming drug resistance mechanisms employed by cancer cells, focusing on emerging therapeutic modalities. The intricate molecular insights into drug resistance, including genetic mutations, efflux pumps, altered signaling pathways, and microenvironmental influences, are discussed. Furthermore, the promising avenues offered by targeted therapies, combination treatments, immunotherapies, and precision medicine approaches are highlighted. Specifically, the synergistic effects of combining traditional cytotoxic agents with molecularly targeted inhibitors to circumvent resistance pathways are examined. Additionally, the evolving landscape of immunotherapeutic interventions, including immune checkpoint inhibitors and adoptive cell therapies, is explored in terms of bolstering anti-tumor immune responses and overcoming immune evasion mechanisms. Moreover, the significance of biomarker-driven strategies for predicting and monitoring treatment responses is underscored, thereby optimizing therapeutic outcomes. For insights into the future direction of cancer treatment paradigms, the current review focused on prevailing drug resistance challenges and improving patient outcomes, through an integrative analysis of these emerging therapeutic strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers16132478

Cites

129 of 129 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Visual overview: understanding drug resistance mechanisms and innovative strategies for overcoming them. Panel (A) details the primary causal determinants contributing to drug resistance, including gene mutations, efflux pumps, alterations in signaling pathways, and tumor heterogeneity. Panel (B) showcases a diverse array of advanced therapy modalities aimed at overcoming the detrimental effects of drug resistance in cancer cells, encompassing targeted therapies, immunotherapies, combination treatments, and emerging molecular interventions.
Figure 1 Visual overview: understanding drug resistance mechanisms and innovative strategies for overcoming them. Panel (A) details the primary causal determinants contributing to drug resistance, including gene mutations, efflux pumps, alterations in signaling pathways, and tumor heterogeneity. Panel (B) showcases a diverse array of advanced therapy modalities aimed at overcoming the detrimental effects of drug resistance in cancer cells, encompassing targeted therapies, immunotherapies, combination treatments, and emerging molecular interventions.CC BY · PubMed Central
Figure 2 Deciphering molecular pathways of drug resistance in cancer cells: pioneering strategies for conquering resistance challenges, unraveling causal determinants versus harnessing advanced tools and techniques for resisting drug resistance.
Figure 2 Deciphering molecular pathways of drug resistance in cancer cells: pioneering strategies for conquering resistance challenges, unraveling causal determinants versus harnessing advanced tools and techniques for resisting drug resistance.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 129 references

Cited by

See all 372

Metadata

Authors
Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S.
Affiliations
  • GLA University (IN)
  • City Of Hope National Medical Center (US)
Corresponding author
Singhal, Sharad S.
Venue
Cancers
Publisher
MDPI AG
Published
2024-07-07
Volume
16
Issue
13
Pages
2478
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4400418891
Cited by
339
References
129
Citations by year
2026: 165 · 2025: 167 · 2024: 6
FWCI
57.57
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Cancer Institute of the National Institutes of Health (P30CA33572, W81XWH-22-1-0331, HT9425-23-1-0581)
  • United States Department of Defense (P30CA33572, W81XWH-22-1-0331, HT9425-23-1-0581)
  • City of Hope’s Beckman Research Institute (P30CA33572, W81XWH-22-1-0331, HT9425-23-1-0581)
Topics
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
chemoresistance, efflux pumps, genetic mutations, tumor microenvironment, targeted therapy, combination therapy, immunotherapy, immune checkpoint inhibitors, adoptive immunotherapy, biomarkers, precision medicine, antitumor immunity, immune evasion

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells. https://app.cochat.ai/papers/10.3390/cancers16132478
The paper
Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024). Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells. Cancers. https://doi.org/10.3390/cancers16132478

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.